The APLAR Recommendations for the Management of Psoriatic Arthritis
7
Issued Date
2025-08-01
Resource Type
ISSN
17561841
eISSN
1756185X
Scopus ID
2-s2.0-105011974627
Journal Title
International Journal of Rheumatic Diseases
Volume
28
Issue
8
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Rheumatic Diseases Vol.28 No.8 (2025)
Suggested Citation
Leung Y.Y., Bird P., Haroon M., Kishimoto M., Shin K., Mathew A.J., Reyes H., Chau J., Neuen D., Chiowchanwisawakit P., Ridha A.A., Xu C., Taylor W., Yahya F., So H., Fukui S., Van Hung N., Soroosh S.G., Wahono C.S., Pok L.S.L., Gonzales J.R., Yeo Y.W., Dandeniya C., Morita A., Rahman P.A., Basim S., Deshapriya K., Satti E., Phong N.D., Kim M.J., Jha A., Cackamvalli P.M., Rafique A., Islam M.N., Tam L.S. The APLAR Recommendations for the Management of Psoriatic Arthritis. International Journal of Rheumatic Diseases Vol.28 No.8 (2025). doi:10.1111/1756-185x.70372 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/111509
Title
The APLAR Recommendations for the Management of Psoriatic Arthritis
Author(s)
Leung Y.Y.
Bird P.
Haroon M.
Kishimoto M.
Shin K.
Mathew A.J.
Reyes H.
Chau J.
Neuen D.
Chiowchanwisawakit P.
Ridha A.A.
Xu C.
Taylor W.
Yahya F.
So H.
Fukui S.
Van Hung N.
Soroosh S.G.
Wahono C.S.
Pok L.S.L.
Gonzales J.R.
Yeo Y.W.
Dandeniya C.
Morita A.
Rahman P.A.
Basim S.
Deshapriya K.
Satti E.
Phong N.D.
Kim M.J.
Jha A.
Cackamvalli P.M.
Rafique A.
Islam M.N.
Tam L.S.
Bird P.
Haroon M.
Kishimoto M.
Shin K.
Mathew A.J.
Reyes H.
Chau J.
Neuen D.
Chiowchanwisawakit P.
Ridha A.A.
Xu C.
Taylor W.
Yahya F.
So H.
Fukui S.
Van Hung N.
Soroosh S.G.
Wahono C.S.
Pok L.S.L.
Gonzales J.R.
Yeo Y.W.
Dandeniya C.
Morita A.
Rahman P.A.
Basim S.
Deshapriya K.
Satti E.
Phong N.D.
Kim M.J.
Jha A.
Cackamvalli P.M.
Rafique A.
Islam M.N.
Tam L.S.
Author's Affiliation
UNSW Sydney
Chinese University of Hong Kong
Universiti Malaya
Seoul National University College of Medicine
University of Baghdad
Seoul National University Hospital
Royal Prince Alfred Hospital
Duke-NUS Medical School
Singapore General Hospital
Brawijaya University
Siriraj Hospital
Christian Medical College, Vellore
Tan Tock Seng Hospital
Nagoya City University Graduate School of Medical Sciences
Hamad Medical Corporation
Lee Kong Chian School of Medicine
University of the Philippines Manila
Kyorin University Faculty of Medicine
Kyorin University
Hanoi Medical University
Bangabandhu Sheikh Mujib Medical University
Baghdad Teaching Hospital
Faculty of Medicine, University of Peradeniya
Bach Mai Hospital
Rheumatology Research Center
Hutt Hospital
Fatima Memorial Hospital
Teaching Hospital
Patient Research Partner
Patient Research Partner
Chinese University of Hong Kong
Universiti Malaya
Seoul National University College of Medicine
University of Baghdad
Seoul National University Hospital
Royal Prince Alfred Hospital
Duke-NUS Medical School
Singapore General Hospital
Brawijaya University
Siriraj Hospital
Christian Medical College, Vellore
Tan Tock Seng Hospital
Nagoya City University Graduate School of Medical Sciences
Hamad Medical Corporation
Lee Kong Chian School of Medicine
University of the Philippines Manila
Kyorin University Faculty of Medicine
Kyorin University
Hanoi Medical University
Bangabandhu Sheikh Mujib Medical University
Baghdad Teaching Hospital
Faculty of Medicine, University of Peradeniya
Bach Mai Hospital
Rheumatology Research Center
Hutt Hospital
Fatima Memorial Hospital
Teaching Hospital
Patient Research Partner
Patient Research Partner
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: Under the auspices of the Asia-Pacific League of Associations for Rheumatology (APLAR), we aimed to develop broad, evidence- and consensus-based guidelines to aid health professionals managing patients with psoriatic arthritis (PsA) in the region. Methods: A working group of 35 members comprising rheumatologists, dermatologists, and patient research partners from 18 APLAR countries was convened. The working group conducted systematic literature reviews to derive the quality of evidence via GRADE methods in supporting the efficacy and safety of classes of therapeutic agents for the management of active PsA, its comorbidities, and screening for specific infection concerns in the region. Recommendation statements on the principles of management and the best use of therapeutic drugs were developed. Consensus within the working group was achieved. An external voting panel, five from each of the 18 APLAR countries, was convened to confirm further agreement on the recommendation statements. Results: The main literature review included 178 articles from clinical trials for PsA. Additional articles on the evidence for managing comorbidities, uveitis, inflammatory bowel disease, and screening for chronic hepatitis B and latent tuberculosis were reviewed. The working group discussed and reached consensus on eight management principles and 16 recommendation statements for managing PsA. Endorsement from an external voting panel (n = 90, response rate 80%) was achieved. Conclusion: These first recommendations for the management of PsA patients in the APLAR regions were developed based on the best available evidence and region-specific considerations through discussion among rheumatologists, dermatologists, and patients, with strong agreement from an external expert panel.